Preliminary Programme of CML Horizons 2012 Patient Advocacy Conference
11-13 May 2012, Leonardo Royal Hotel, Munich, Germany

Preliminary – subject to change!

Programme overview:

<table>
<thead>
<tr>
<th>Fri 11 May</th>
<th>Sat 12 May</th>
<th>Sun 13 May</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00-10:30</td>
<td>09:00-10:30</td>
<td>09:00-10:30</td>
</tr>
<tr>
<td>Tai Chi/Yoga (tbc)</td>
<td>CML2: Best Standard of Care</td>
<td>CML4 - Research and future outlook</td>
</tr>
<tr>
<td>Coffee break</td>
<td>Coffee break</td>
<td>Coffee break</td>
</tr>
<tr>
<td>11:00-12:30</td>
<td>11:00-12:30</td>
<td>11:00-12:30</td>
</tr>
<tr>
<td>Lunch</td>
<td>ADV2: Expert Marketplace</td>
<td>ADV4: Communicating your message</td>
</tr>
<tr>
<td>13:00-14:30</td>
<td>13:00-14:30</td>
<td>13:00-14:30</td>
</tr>
<tr>
<td>Opening Update CML Advocates Network</td>
<td>CML3: Monitoring CML</td>
<td>---</td>
</tr>
<tr>
<td>14:30-15:30</td>
<td>14:30-15:30</td>
<td>14:30-15:30</td>
</tr>
<tr>
<td>ADV1: Bringing down access barriers</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>16:00-17:30</td>
<td>16:00-17:30</td>
<td>16:00-17:30</td>
</tr>
<tr>
<td>CML1: Side Effect Management &amp; CAM</td>
<td>ADV3: CML Advocacy Marketplace</td>
<td>Potentially: CML lab tour for those staying in Munich (tbc)</td>
</tr>
<tr>
<td>07:00</td>
<td>07:30</td>
<td>Dinner</td>
</tr>
</tbody>
</table>

ADV = Advocacy Session, CML = Disease specific session

Key coordinates of the conference:

- Governed by global CML Steering Committee
- Formally hosted by Leukemia Patient Advocates Foundation, Switzerland
- Participants: 80-90 patient representatives from 50 countries, +faculty +sponsors
- Conference language: English
- Multi-sponsored conference

Session Details – Topics covered in each session:

**CML1: Side Effect Management & CAM**
- Complementary Medicines and Drug-Drug Interactions
- Side Effect Management

**CML2: Best standard care in CML**
- Update on approved TKIs
- Interferon + stopping therapies
- Stem Cell Transplantation

**CML3: Monitoring CML**
- Basics of monitoring CML
- Quality in CML diagnostics
- New developments and innovation in CML monitoring
CML4  Research and future outlook in CML
  - New drugs - emerging therapies
  - Targeting stem cells and eradicating CML

ADV1  Access - bringing down the barriers
  - Keynote: Overview on access challenges globally
  - Access to Diagnostics & Monitoring: Example Ethiopia
  - Access to Clinical Trials: Example Latin America
  - Access to Treatment: Example Asia

ADV2  Expert Marketplace
  - Adherence
  - Drug Drug Interaction
  - Cancer & the family
  - Fundraising

ADV3  Advocacy Marketplace
  - Call for abstracts by CML Advocates Network members,
  - Selection of Steering Committee will be presented here

ADV4  Communicating your message
  - How NGOs can bring about their message, create awareness, and campaign for the cause

COM  Patient Engagement Forum
  - Fostering the dialogue between delegates and those responsible for patient relations in industry – Q&A sessions in rotating groups

**Marketplace Sessions (ADV2, ADV3, Patient Engagement Forum)**

The Marketplace is a highly interactive session with very short flipchart presentations and concise, focused discussions. The aim of the Marketplace is to provide participants with the opportunity to discuss topics with experts in an informal, small group setting.

The marketplace consists of 4-6 “market stalls” each covering a different topic. Speakers will stay at their market stall for the entire Marketplace whilst the participants will move from one stall to the next. The focus of discussion during each short session will depend on the needs/interest of the group. After 25 minutes a bell will ring and participants will have 5 minutes to move to the next market stall. The short sessions will be repeated 3 times during the hour period.

In the expert marketplace, an expert speaker has been selected by the Steering Committee. In the advocacy marketplace, participants will submit abstracts prior to the conference, of which some will be invited to be presented. Posters will be suggested for those not having been selected.